RINVOQ LQ

GrowthSM

upadacitinib

NDAORALSOLUTION
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Janus Kinase Inhibitors

Pharmacologic Class:

Janus Kinase Inhibitor

Clinical Trials (5)

NCT07425899Phase 1Not Yet Recruiting

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Started Feb 2026
32 enrolled
Healthy Volunteer
NCT07258771Phase 4Recruiting

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Started Jan 2026
110 enrolled
Ulcerative Colitis Acute
NCT07073079N/ARecruiting

A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

Started Jul 2025
250 enrolled
Crohn's Disease
NCT07023302Phase 3Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Started Jun 2025
123 enrolled
Alopecia Areata
NCT06838845N/ARecruiting

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

Started Apr 2025
80 enrolled
Ulcerative Colitis

Loss of Exclusivity

LOE Date
Oct 17, 2036
129 months away
Patent Expiry
Oct 17, 2036
Exclusivity Expiry
Apr 26, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
8962629
Jan 15, 2031
Substance
U-3945
RE47221
Aug 16, 2033
Substance
11661425
Oct 17, 2036
Substance
11680069
Oct 17, 2036
Substance
11718627
Oct 17, 2036
Substance